Researchers continue fight to cure cervical cancer
Safe to be given to women ages 9 to 26, the purpose of the vaccine is to offer protection from infection and diseases associated with “high- risk” HPV types that cause approximately 70 percent of cervical cancers. The vaccine also blocks the “low-risk” types found with most cases of genital warts.
Human papilomavirus is the name of a group of viruses that infect the skin. Typically, HPV results in warts that can occur on different areas of the body, including the genitals. HPV has also been linked to abnormal cell changes in the cervix and is thought to be a contributing factor to some cervical cancer cases that are diagnosed through Pap screenings by a gynecologist.
In many cases, HPV is asymptomatic, meaning a person does not even know he or she has it let alone able to spread it. There are more than 100 types of HPV and 30 types are transmitted sexually and result in genital warts. It is considered the most common sexually transmitted disease. Genital HPV is spread through skin-on-skin-contact, not bodily fluids, so condom use is not entirely effective in preventing transmission.
According to research, about 5.5 million new genital HPV cases occur each year, and approximately 20 million people – men and women – are thought to have an active HPV infection at any given time.
Being classified as an STD has made HPV a topic that wasn’t widely discussed. However, upon discovery of the link to cervical cancer and treatment possibilities, HPV is now being discussed by men and women.
According to the CDC, approximately 10 of the 30 identified genital HPV types can lead, in rare cases, to development of cervical cancer. The American Cancer Society estimates that 10,000 women will develop invasive cervical cancer and about 4,000 women will die from this disease each year.
While there was once no cure for HPV, new hope lies in the vaccine, which significantly reduced the combined incidence of persistent HPV 6, 11, 16, or 18 infection and related diseases, including new cervical precancers and genital warts compared with a placebo in a study published in “The Lancet Oncology.” The vaccine will be used as a prophylactic in women of the determined age group, a notion that has caused controversy among some religious groups.
Some conservative groups have billed the new drug as a “promiscuity vaccine,” saying it will give teens a reason to think casual sex just got a little safer. But proponents of the drug say that it is a viable option against cervical cancer and that message should be put above all others. After all, while tetanus shots are given to ward off lockjaw, those who receive them do not go seeking out rusty nails. Perhaps the same will be said for those receiving the vaccine.
For more information on HPV and cervical cancer testing and treatment, visit your local gynecologist.
